Scleroderma can take several different forms, and even within the same form the progression and severity of symptoms can vary greatly from patient to patient. In some patients, symptoms will develop with a surprising rapidity while, in others, symptoms may take years to develop. For a more detailed information about this disease pleas visit our Scleroderma page.
A Phase II Multi-Center Study for scleroderma will be opening soon. To find out if you have the criteria to be eligible for this study visit our Scleroderma Study page.
The Colorado Blood Cancer Institute in collaboration with National Jewish Hospital are seeking to find a treatment to cure this debilitating disease. Dr. Richard Nash and Dr. McSweeney of the Colorado Blood Cancer Institute will be leading this transplant study in collaboration with Dr. Aryeh Fischer of National Jewish Hospital in Denver, CO.
National Jewish Hospital and Dr. Aryeh Fischer
Dr. Fischer is Acting Chief of Rheumatology, co-Director of the Autoimmune Lung Center, and Associate Professor of Medicine at National Jewish Health. He also is Director of the University of Colorado Scleroderma Clinic. Dr. Fischer is a Medical Advisory Board Member for the National Scleroderma Foundation and the Pulmonary Fibrosis Foundation. He has developed clinical expertise with patients referred nationally for evaluation of systemic sclerosis and a variety of rheumatologic conditions and autoimmune lung diseases. Dr. Fischer has research interests in systemic sclerosis in general and in the arena of systemic sclerosis associated lung disorders in particular. He is co-investigator on a number of studies involving systemic sclerosis including: “PHAROS” (Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma) registry, Scleroderma Lung Study II, rituximab for systemic sclerosis-associated pulmonary arterial hypertension, and two stem cell transplant protocols for severe systemic sclerosis.
This study is funded by the Scleroderma Research Foundation